News
12 Health Care Stocks Moving In Thursday's After-Market Session
11 Apr 24
Movers
Ocuphire Pharma Announces First Patient Enrolled In LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) For The Treatment Of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
11 Apr 24
Biotech, News, General
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
26 Mar 24
Long Ideas, News, Penny Stocks, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
Alliance Global Partners Maintains Buy on Ocuphire Pharma, Lowers Price Target to $20
20 Mar 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target
11 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Ocuphire Pharma Q4 2023 GAAP EPS $(0.210) vs $(0.050) Estimate, Sales $1.700M
8 Mar 24
Earnings, Earnings Misses, News
Ocuphire Pharma Strengthens Leadership Team with Key Appointments; Nirav Jhaveri, C.F.A, M.B.A. Appointed As Chief Financial Officer
14 Feb 24
News, Management
Ocuphire Pharma Announces Presentation On APX3330 At The Annual Angiogenesis, Exudation, And Degeneration 2024 Conference
5 Feb 24
Biotech, News, General
Press releases
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
11 Apr 24
Press Releases
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
23 Feb 24
News, Press Releases
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 Jan 24
Markets, Press Releases